

## IN THE CLAIMS:

*No Admission.* The claims presented below are labeled pursuant to the request of the Patent and Trademark Office for convenience in examination. Reference to a claim as "currently amended" is not an admission that the claim was altered for any reason related to patentability.

1. (Currently Amended) A humanized antibody or subsequence thereof that binds ICAM-1, said antibody comprising i) SEQ ID NO:5 and SEQ ID NO:7 (HumB), or; ii) a subsequence of SEQ ID NO:5 and/or SEQ ID NO:7; or iii) SEQ ID NO:5 and SEQ ID NO: 7 wherein an acceptor variable framework region of SEQ ID NO:5 and/or SEQ ID NO:7 has at least one non-human donor amino acid or a subsequence thereof, wherein a variable framework region of the humanized antibody has had at least one non-human amino acid substituted with a human amino acid.
2. (Cancelled)
3. (Currently Amended) The antibody subsequence of claim 1 or claim 84, wherein the antibody subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)<sub>2</sub> fragment.
4. (Cancelled)
5. (Currently Amended) A humanized antibody that binds ICAM-1 and is capable of inhibiting~~inhibits~~ human rhinovirus (HRV) infection of cells expressing ICAM-1, said antibody having V<sub>H</sub> and a V<sub>L</sub> regions comprising SEQ ID NO:5 and SEQ ID NO: 7 wherein an acceptor variable framework region of SEQ ID NO: 5 and/or SEQ ID NO:7 an amino acid substitution in a human consense variable region sequence~~the humanized antibody has had one or more non-human amino acids substituted with an amino acid of a human consensus variable framework region sequence~~, and wherein the protective efficacy against human rhinovirus (HRV) is greater than a non-humanized antibody containing the variable domains of mouse monoclonal antibody denoted as 1A6.
6. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 2 times greater than a non-humanized antibody containing the variable domains of 1A6 antibody.

7. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 5 times greater than a non-humanized antibody containing the variable domains of 1A6 antibody.
8. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 10 times greater than a non-humanized antibody containing the variable domains of 1A6 antibody.
9. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 20 times greater than a non-humanized antibody containing the variable domains of 1A6 antibody.
10. (Currently Amended) The humanized antibody of claim 5, said antibody having a protective efficacy at least 30 times greater than a non-humanized antibody containing the variable domains of 1A6 antibody.
11. (Cancelled)
12. (Cancelled)
13. (Currently Amended) The humanized antibody of any one of claims 1, 5, or 84~~claim 5,~~ comprising 2 full-length heavy chains and 2 full-length light chains.
14. (Cancelled)
15. (Currently Amended) The humanized antibody subsequence of claim ~~5~~1, wherein the antibody subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)<sub>2</sub> fragment.
16. (Previously Presented) The humanized antibody of claim 1 or 5, wherein the humanized antibody is multispecific or multifunctional.
17. (Currently Amended) The humanized antibody of any one of claims 1, 5, or 84~~claim 1 or 5,~~ wherein the humanized antibody is linked to one or more identical or different antibodies to form a multimer.

18. (Previously Presented) The humanized antibody of claim 17, wherein the multimer comprises a homo- or hetero-dimer, trimer, or tetramer.
19. (Previously Presented) The humanized antibody of claim 17, wherein the multimer is formed via a multimerization domain.
20. (Previously Presented) The humanized antibody of claim 19, wherein the multimerization domain comprises a human amino acid sequence.
21. (Previously Presented) The humanized antibody of claim 19, further comprising a linker located between the multimerization domain and the humanized antibody.
22. (Currently Amended) A humanized antibody capable of inhibiting ~~that inhibits~~ human rhinovirus (HRV) infection of cells comprising V<sub>H</sub> and a V<sub>L</sub> regions having amino acid sequences comprising i) SEQ ID NO:5 and SEQ ID NO: 7, or ii) SEQ ID NO:5 and SEQ ID NO: 7 wherein an acceptor variable framework region of one or both of the preceding comprises at least one non-human donor amino acid~~SEQ ID NO:5 and 7 (HumB) or a subsequence thereof, wherein a variable framework region of the humanized antibody has had one or more non-human amino acids substituted with an amino acid of a human consensus variable framework region sequence.~~
23. (Previously Presented) The humanized antibody of claim 22, comprising 2 full-length heavy chain polypeptides and 2 full-length light chain polypeptides.
24. (Previously Presented) The humanized antibody of claim 22, wherein the subsequence comprises a single chain, Fv, Fab, Fab' or (Fab)<sub>2</sub> fragment.
25. (Previously Presented) The humanized antibody of claim 22, wherein the humanized antibody is linked with other identical or different antibodies to form a multimer.
26. (Previously Presented) The humanized antibody of claim 25, wherein the multimer comprises a homo-or hetero-dimer, trimer, or tetramer.
27. (Currently amended) The humanized antibody of claim 25, wherein the different antibodies are human, humanized, chimeric or non-human.

28. (Currently Amended) A nucleic acid sequence encoding a humanized antibody of any one of claims 1, 5, or 22 or 84 or a subsequence thereof.
29. (Previously Presented) An expression cassette comprising the nucleic acid sequence of claim 28 operably linked to an expression control element.
30. (Previously Presented) A vector comprising the nucleic acid sequence of claim 29.
31. (Previously Presented) A vector of claim 30, wherein the nucleic acid sequence is operably linked to an expression control element.
32. (Previously Presented) A cell comprising the nucleic acid sequence of claim 28.
33. (Previously presented) The cell of claim 32, wherein the cell is prokaryotic or eukaryotic.
34. (Currently Amended) A pharmaceutical composition comprising a humanized antibody of any one of claims 1, or 5, 22 or 84 and a pharmaceutically acceptable carrier.
35. (Previously Presented) The pharmaceutical composition of claim 34, wherein the carrier is compatible with inhalation or nasal delivery to a subject.
36. (Current Amended) A method of inhibiting human rhinovirus (HRV) infection of a cell comprising contacting ~~(HRV)~~ or a cell with an amount of a humanized antibody of any one of claims 1, 5, 22, or 84~~claims 1 or 5~~, sufficient to inhibit human rhinovirus (HRV)infection of the cell.
37. (Current Amended) The method of claim 36, wherein the cell is ~~present~~presented in a subject.
38. (Previously Presented) The method of claim 37, wherein the cell is an epithelial cell.
39. (Previously Presented) The method of claim 37, wherein the cell expresses ICAM-1.
40. (Currently Amended) A method of inhibiting human rhinovirus (HRV)infection of a cell comprising contacting ~~(HRV)~~ or a cell susceptible to human rhinovirus (HRV)infection

with an amount of a humanized antibody of any one of claims 1, 5, 22, or 84~~claim 22~~ effective to inhibit human rhinovirus (HRV)infection of the cell.

41. (Previously Presented) The method of claim 40, wherein the cell is present in a subject.
42. (Previously Presented) The method of claim 41, wherein the subject has or is at risk of having asthma.
43. (Previously Presented) The method of claim 40, wherein the antibody binds to an antigen present on the surface of the cell.
44. (Previously Presented) The method of claim 40, wherein the cell expresses ICAM-1.
45. (Previously Presented) The method of claim 40, wherein the cell is an epithelial cell.
46. (Previously Presented) The method of claim 40, wherein the humanized antibody is administered locally.
47. (Previously presented) The method of claim 40, wherein the humanized antibody is administered via inhalation or intranasally.
48. (Currently Amended) A method of inhibiting human rhinovirus (HRV)infection, inhibiting human rhinovirus (HRV)progression or treating human rhinovirus (HRV)infection of a subject comprising administering to a subject having or at risk of having HRV infection an amount of a humanized antibody of any one of claims 1, 5, 22, or 84~~claim 22~~ effective to inhibit progression or treat human rhinovirus (HRV)infection of the subject.
49. (Previously Presented) The method of claim 48, wherein the humanized antibody is administered locally.
50. (Previously presented) The method of claim 48, wherein the humanized antibody is administered via inhalation or intranasally.
51. (Previously Presented) The method of claim 48 wherein the subject has or is at risk of having asthma.

52. (Previously presented) The method of claim 48, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18 years.
53. (Currently Amended) A method of decreasing or inhibiting a symptom of the common cold in a subject comprising administering to a subject having a common cold an amount of a humanized antibody of claim any one of claims 1, 5, 22 or 84~~22~~ effective to decrease or inhibit one or more symptoms of the common cold in the subject.
54. (Previously Presented) The method of claim 55, wherein the humanized antibody is administered locally.
55. (Previously presented) The method of claim 53, wherein the humanized antibody is administered via inhalation or intranasally.
56. (Previously Presented) The method of claim 53, wherein the subject has or is at risk of having asthma.
57. (Previously presented) The method of claim 53, wherein the subject is a newborn or between the ages of 1 to 5, 5 to 10 or 10 to 18 years.
58. (Cancelled)
59. (Cancelled)
60. (Currently Amended) The humanized antibody of any one of claims 1, 5, 22 or 84[[4]], wherein said variable framework region substitution comprises 5-10 human donor amino acids.
61. (Currently Amended) The humanized antibody of claim any one of claims 1, 5, 22 or 84[[4]], wherein said variable framework region substitution comprises 3-5 human donor amino acids.
62. (Currently Amended) The humanized antibody of any one of claims~~claim~~ 1, 5, 22, and 84[[4]], wherein said variable framework region substitution comprises 1-3 human donor amino acids.

63. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the ~~substituted~~ humanized antibody binds ICAM-1 with increased affinity relative to ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
64. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the substituted antibody binds ~~has~~ ICAM-1 with an binding affinity 4-fold greater than unsubstituted humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
65. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the ~~substituted~~ humanized antibody binds ~~has~~ ICAM-1 with an binding affinity 5-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
66. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the ~~substituted~~ humanized antibody binds ~~has~~ ICAM-1 with an binding affinity 5 to 8-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
67. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the ~~substituted~~ humanized antibody binds ~~has~~ ICAM-1 with an binding affinity 5 to 10-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
68. (Currently Amended) The humanized antibody of any one of claims ~~1~~ 1, 5, 22, or 84[[4]], wherein the ~~substituted~~ humanized antibody binds ~~has~~ ICAM-1 with an binding affinity 8 to 15-fold greater than ~~unsubstituted~~ humanized antibody having the

complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.

69. (Currently Amended) The humanized antibody of claim 1, 5 or 22[[4]], wherein the substituted antibody binds ~~has~~ ICAM-1 with an binding affinity 10 to 20-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
70. (Currently Amended) The humanized antibody of claim 1, 5 or 22[[4]], wherein the substituted antibody binds ~~has~~ ICAM-1 with an binding affinity 20 to 40-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
71. (Currently Amended) The humanized antibody of ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the substituted antibody binds ~~has~~ ICAM-1 with an binding affinity 50 to 100-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
72. (Currently Amended) The humanized antibody of claim ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the substituted antibody binds ~~has~~ ICAM-1 with an binding affinity more than 100-fold greater than ~~unsubstituted~~ humanized antibody having the complementarity determining regions of mouse monoclonal antibody denoted as 1A6 and no donor amino acids in the acceptor variable framework region.
73. (Currently Amended) The humanized antibody of ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the ~~unsubstituted~~ antibody binds ICAM-1 with an affinity greater than a non-humanized antibody containing the variable domains of 1A6 antibody.
74. (Currently Amended) The humanized antibody of ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the substituted antibody binds ICAM-1 with increased affinity relative to

~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~

75. (Currently Amended) The humanized antibody of claim ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the ~~substituted~~antibody binds ICAM-1 with a binding affinity that is 4-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~
76. (Currently Amended) The humanized antibody of claim ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 5-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~
77. (Currently Amended) The humanized antibody of ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 5 to 8-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~
78. (Currently Amended) The humanized antibody of ~~any one of claims~~claim 1, 5, 22, or 84[[4]], wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 5 to 10-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~
79. (Currently Amended) The humanized antibody of claim 4, wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 8 to 15-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~
80. (Currently Amended) The humanized antibody of claim 4, wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 10 to 20-fold greater than ~~mouse monoclonal antibody as 1A6a non-humanized antibody containing the variable domains of 1A6 antibody.~~

81. (Currently Amended) The humanized antibody of claim 4, wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 20 to 40-fold greater than ~~mouse monoclonal antibody as 1A6~~a non-humanized antibody containing the variable domains of 1A6 antibody.
82. (Currently Amended) The humanized antibody of claim 4, wherein the ~~substituted~~antibody has an ICAM-1 binding affinity 50 to 100-fold greater than ~~mouse monoclonal antibody as 1A6~~a non-humanized antibody containing the variable domains of 1A6 antibody.
83. (Currently Amended) The humanized antibody of claim 4, wherein the ~~substituted~~antibody has an ICAM-1 binding affinity more than 100-fold ~~or greater than mouse monoclonal antibody as 1A6~~a non-humanized antibody containing the variable domains of 1A6 antibody.

**Please add the following new claims:**

84. (New) A antibody or subsequence thereof comprising SEQ ID NO:5 and SEQ ID NO: 7.
85. (New) A antibody or subsequence thereof comprising:
  - i) SEQ ID NO:5 and SEQ ID NO: 7; or
  - ii) SEQ ID NO:5 and SEQ ID NO: 7 wherein an acceptor variable framework region of one or both of the preceding has at least one non-human donor amino acid,

wherein said antibody binds ICAM-1.
86. (New) A antibody of any one of claims 1, 5, 22, 84 or 85 comprising a single chain Fv.
87. (New) A antibody of any one of claims 1, 5, 22, 84 or 85 comprising a Fab.
88. (New) A antibody of any one of claims 1, 5, 22, 84 or 85 comprising a Fab'.
89. (New) A antibody of any one of claims 1, 5, 22, 84 or 85 comprising a (Fab)<sub>2</sub> fragment.
90. (New) A antibody of any one of claims 1, 5, 22, 84 or 85 comprising a monoclonal antibody.

91. (New) A antibody of any one of claims 1, 5, 22, 84-89 or 90 linked to one or more identical or different antibodies to form a multimer.
92. (New) A antibody of any one of claims 1, 5, 22, 84-90 or 91 comprising one or more amino acid additions, deletions, or substitutions.
93. (New) A antibody of claim 92 comprising between 1 and 3 amino acid substitutions.
94. (New) A antibody of claim 92 comprising between 3 and 5 amino acid substitutions.
95. (New) A antibody of claim 92 comprising between 5 and 10 amino acid substitutions.
96. (New) A antibody of any one of claims 92-95 wherein said amino acid addition, deletion, or substitution occurs in one or both of SEQ ID NO:5 or SEQ ID NO: 7.